DE69228777D1 - Zur Beeinflussung des retikuloendothelialen Systems geeignetes Arzneimittel - Google Patents

Zur Beeinflussung des retikuloendothelialen Systems geeignetes Arzneimittel

Info

Publication number
DE69228777D1
DE69228777D1 DE69228777T DE69228777T DE69228777D1 DE 69228777 D1 DE69228777 D1 DE 69228777D1 DE 69228777 T DE69228777 T DE 69228777T DE 69228777 T DE69228777 T DE 69228777T DE 69228777 D1 DE69228777 D1 DE 69228777D1
Authority
DE
Germany
Prior art keywords
influencing
acid
acidic
neutral
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69228777T
Other languages
English (en)
Other versions
DE69228777T2 (de
Inventor
Jozsef Dr Beres
Jun Juzsef Dr Beres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beres Export-Import RT
Original Assignee
Beres Export-Import RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beres Export-Import RT filed Critical Beres Export-Import RT
Application granted granted Critical
Publication of DE69228777D1 publication Critical patent/DE69228777D1/de
Publication of DE69228777T2 publication Critical patent/DE69228777T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Electrotherapy Devices (AREA)
  • Circuits Of Receivers In General (AREA)
DE69228777T 1991-07-24 1992-07-24 Zur Beeinflussung des retikuloendothelialen Systems geeignetes Arzneimittel Expired - Fee Related DE69228777T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU912492A HU207799B (en) 1991-07-24 1991-07-24 Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis

Publications (2)

Publication Number Publication Date
DE69228777D1 true DE69228777D1 (de) 1999-05-06
DE69228777T2 DE69228777T2 (de) 1999-10-21

Family

ID=10959658

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228777T Expired - Fee Related DE69228777T2 (de) 1991-07-24 1992-07-24 Zur Beeinflussung des retikuloendothelialen Systems geeignetes Arzneimittel

Country Status (18)

Country Link
US (2) US5312629A (de)
EP (1) EP0524633B1 (de)
JP (1) JP2673852B2 (de)
KR (1) KR100234855B1 (de)
AT (1) ATE178213T1 (de)
BG (1) BG61250B1 (de)
CA (1) CA2074639C (de)
CZ (1) CZ281672B6 (de)
DE (1) DE69228777T2 (de)
FI (1) FI923364A (de)
HR (1) HRP920192B1 (de)
HU (1) HU207799B (de)
PL (1) PL169684B1 (de)
RO (1) RO109505B1 (de)
RU (1) RU2093160C1 (de)
SI (1) SI9200155A (de)
SK (1) SK278944B6 (de)
YU (1) YU48243B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871779A (en) * 1994-01-18 1999-02-16 Mount Sinai Hospital Corporation Treatment of arthropathies with vanadate compounds or analogues thereof
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US5863519A (en) * 1994-08-18 1999-01-26 Nycomed Imaging As Composition and method of MRI using both a positive and a negative contrast agent
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
GB9416768D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
WO1996005867A2 (en) * 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
RU2146146C1 (ru) * 1999-05-05 2000-03-10 Дубинина Лариса Васильевна Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
US20030170318A1 (en) * 2000-09-29 2003-09-11 Steiner Gregory Gene Fluoride compositions and uses thereof
US6638431B2 (en) * 2001-05-03 2003-10-28 Mainstream Engineering Corporation Formulation and method for treating wetted surface elements in climate control systems
KR100889994B1 (ko) * 2003-08-14 2009-03-24 한영미 녹반을 함유하는 항암활성을 갖는 조성물
KR20050018250A (ko) * 2003-08-14 2005-02-23 한영주 복합생약 조성물을 함유하는 항암활성을 갖는 조성물
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
RU2437565C2 (ru) * 2005-06-02 2011-12-27 Ю. Эс. Боракс Инк. Композиция кормового продукта для профилактики или лечения остеохондроза (варианты), способ профилактики или лечения остеохондроза
JP2010512323A (ja) * 2006-12-06 2010-04-22 ユー．エス．ボラックス インコーポレイテッド 動物飼料組成物
US8008035B2 (en) 2007-01-25 2011-08-30 Roche Diagnostics Operations, Inc. Enhancement of vanadium-containing phosphatase inhibitors
EP1949894B1 (de) * 2007-01-25 2016-06-29 Roche Diagnostics GmbH Verstärkung von vanadiumhaltigen Phosphatasehemmern mit Polyole
US10634385B2 (en) 2009-09-03 2020-04-28 Ademco Inc. Heat balancing system
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
WO2014196841A1 (en) 2013-06-07 2014-12-11 Kael-Gemvax Co., Ltd. Biological markers useful in cancer immunotherapy
JP6495899B2 (ja) 2013-06-21 2019-04-03 ジェムバックス アンド カエル カンパニー，リミティド ホルモン分泌調節剤、及びそれを含む組成物
EP3085380B1 (de) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Zusammensetzung zur behandlung von prostatakrebs
WO2015126265A1 (en) * 2014-02-18 2015-08-27 Santos Joyce Bedelia B Oral liquid vitamin supplements containing zinc and stabilized vitamin c with reduced astringency
JP6420459B2 (ja) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (de) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptid zur verhinderung von hörverlust und zusammensetzung damit
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2022998B (en) * 1978-06-14 1982-09-08 Beres J Phermaceutical composition for the treatment of neoplasticand other diseases
JPS554348A (en) * 1978-06-26 1980-01-12 Peresu Yozefu Drug composition for treating variety of illness by influence to reticuloendotherial tissue and method of treating maligmant tumor with said composition in treating human

Also Published As

Publication number Publication date
BG61250B1 (bg) 1997-04-30
HUT61475A (en) 1993-01-28
YU48243B (sh) 1997-08-22
FI923364A0 (fi) 1992-07-24
CA2074639A1 (en) 1993-01-25
HRP920192B1 (en) 2000-06-30
KR100234855B1 (ko) 1999-12-15
PL169684B1 (pl) 1996-08-30
JP2673852B2 (ja) 1997-11-05
PL295352A1 (en) 1993-02-22
RU2093160C1 (ru) 1997-10-20
US5405620A (en) 1995-04-11
YU81092A (sr) 1996-01-09
JPH06227992A (ja) 1994-08-16
SI9200155A (en) 1993-03-31
RO109505B1 (ro) 1995-03-30
SK278944B6 (sk) 1998-05-06
EP0524633B1 (de) 1999-03-31
CZ281672B6 (cs) 1996-12-11
HU207799B (en) 1993-06-28
DE69228777T2 (de) 1999-10-21
HU912492D0 (en) 1991-12-30
CZ232692A3 (en) 1993-02-17
US5312629A (en) 1994-05-17
EP0524633A2 (de) 1993-01-27
ATE178213T1 (de) 1999-04-15
HRP920192A2 (hr) 1994-04-30
FI923364A (fi) 1993-01-25
KR930001915A (ko) 1993-02-22
CA2074639C (en) 1996-01-09
BG96686A (bg) 1993-12-24
EP0524633A3 (en) 1993-07-28
SK232692A3 (en) 1995-06-07

Similar Documents

Publication Publication Date Title
DE69228777D1 (de) Zur Beeinflussung des retikuloendothelialen Systems geeignetes Arzneimittel
AU4950096A (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
AU2054097A (en) Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
ES8304797A1 (es) "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".
CA2094540A1 (en) Orally-ingestible nutrition compositions having improved palatability
AU5996996A (en) Al/fe-treatment of a protein solution, followed by membrane concentration
AU5916998A (en) Non-irritating composition for treating acne and other skin conditions
HUT75119A (en) Crystalline anhydrous mycophenolate mofetil, intravenous pharmaceutical formulation thereof and process for their preparation
CA2020858A1 (en) Water treatment agent and water treatment method for boiler
WO2002072077A3 (de) Verwendung von aminosäuren, aminosäureanalogen, zuckerphosphaten und zuckerphosphatanalogen zur behandlung von tumoren, sepsis und zur immunsuppression
GR1002573B (el) Μικροβιακη μεθοδος παρασκευης μεβινολινης.
AU3260093A (en) Use of creatine phosphate or phosphoenolpyruvic acid for the treatment of tumours
FR2672895B1 (fr) Procede de purification d'une proteine fortement glycosylee.
FR2669221B1 (fr) Procede de preparation par compression directe de comprimes de derives de l'acide cephalosporanique.
MY101747A (en) Dihydroorotic acids derivative, processes for preparing the same
HUT72040A (en) Process for the manufacture of aminomethanephosphonic acid
AU2415699A (en) 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid
AU5214900A (en) Pressed products of non-caking salt
IE883296L (en) Vincristine-containing product
ES8800924A1 (es) Procedimiento para la obtencion de benzotiopiranonas
GB1216388A (en) A process for purifying amino acids
BG100733A (en) Therapeutical means for healing the helicovacer pylory infection in vitro
AU660916B2 (en) Beta-hydroxamate D-aspartic acid for treatment of viral infections and tumours
HUP9801499A2 (hu) Metasztázisgátló gyógyászati készítmény és eljárás ennek előállítására
EP0457438A3 (de) Aza-Makrozyklen enthaltende Konjugate und Verfahren zu deren Herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee